Engineered adeno-associated virus capsids

Patent metadata

Field	Value
Publication number	US-2026071237-A1
Application number	US-202519390128-A
Country	US
Kind code	A1
Filing date	Nov 14, 2025
Priority date	Sep 12, 2019
Publication date	Mar 12, 2026
Grant date	—

Abstract

Described herein are methods of generating engineered viral capsid variants. Also described herein are engineered viral capsid variants, engineered viral particles and formulations and cells thereof. Also described herein are vector systems containing an engineered viral capsid polynucleotide and uses thereof.

First claim

What is claimed is:

1 . An adeno-associated virus (AAV) comprising a capsid protein and a polynucleotide encoding a cargo (cargo polynucleotide), wherein the capsid protein comprises a muscle targeting moiety, which comprises an n-mer motif comprising RGDXn, wherein X is any amino acid and n is 4-15, wherein the n-mer motif is located in variable region VIII (VR-VIII), and wherein the cargo polynucleotide is operably linked to a MHCK7 promoter or a CK8 promoter.

2 . The AAV of claim 1 , wherein n is 4.

3 . The AAV of claim 1 , wherein n is 5.

4 . The AAV of claim 1 , wherein the n-mer motif is located in VR-VIII corresponding to the wild-type AAV9 capsid protein.

5 . The AAV of claim 4 , wherein the n-mer motif is located between amino acids 588 and 589 corresponding to the wild-type AAV9 capsid protein or an equivalent position in a wild-type AAV capsid protein of a different serotype

6 . The AAV of claim 1 , wherein the capsid protein comprises an AAV9 capsid protein.

7 . The AAV of claim 1 , wherein the capsid protein comprises an AAVRh74 capsid protein.

8 . The AAV of claim 1 , wherein the cargo polynucleotide is operably linked to the CK8 promoter.

9 . The AAV of claim 1 , wherein the cargo polynucleotide is operably linked to the MHCK7 promoter.

10 . The AAV of claim 1 , wherein the capsid protein comprises an AAV9 capsid protein with one, two, or three amino acid substitution, insertion or deletion.

11 . The AAV of claim 1 , wherein the capsid protein comprises an AAVRh74 capsid protein with one, two, or three amino acid substitution, insertion, or deletion.

12 . The AAV of claim 1 , wherein the cargo comprises a protein for treating a muscular dystrophy.

13 . A method of targeting a muscle cell in a subject in need thereof having a muscular dystrophy comprising administering the AAV of claim 1 to the subject, wherein the cargo is expressed in the muscle cell.

14 . A method of targeting a muscle cell in a subject in need thereof having a muscular dystrophy comprising administering the AAV of claim 2 to the subject, wherein the cargo is expressed in the muscle cell.

15 . A method of targeting a muscle cell in a subject in need thereof having a muscular dystrophy comprising administering the AAV of claim 8 to the subject, wherein the cargo is expressed in the muscle cell.

16 . A method of targeting a muscle cell in a subject in need thereof having a muscular dystrophy comprising administering the AAV of claim 9 to the subject, wherein the cargo is expressed in the muscle cell.

17 . The method of claim 13 , wherein the AAV is capable of transducing the muscle cell more effectively than an AAV without the n-mer motif.

18 . The method of claim 13 , wherein the AAV is capable of inducing faster kinetics of in vivo gene expression in the muscle cell compared to an AAV without the n-mer motif.

Assignees

• Broad Inst Inc
• Harvard College
• Massachusetts Inst Technology

Inventors

• Sabeti Pardis
• Tabebordbar Mohammadsharif
• Ye Simon

Classifications

• C12N2830/50

  regulating RNA stability, not being an intron, e.g. poly A signal · CPC title

• C12N2750/14151

  Methods of production or purification of viral material · CPC title

• C12N2750/14145

  Special targeting system for viral vectors · CPC title

• C12N2750/14142

  virus or viral particle as vehicle, e.g. encapsulating small organic molecule · CPC title

• C12N2750/14123

  Virus like particles [VLP] · CPC title